A PD Solution to Protect Peritoneal Membranes
PD-protecĀ® by Zytoprotec, which now has FDA orphan drug status, is in Phase III trials among 300 patients in the US and Europe. The product aims to reduce PD complications such as peritonitis and membrane failure.
Read the full article » | Posted 01-11-2018
Related Articles
- VenoStent, Inc. is Recruiting Patients for a Clinical Trial of the SelfWrap Posted 10-14-2025
- Diality Treated its First Patient in the Moda-flx Home IDE PRESCRIBE Cinical Trial Posted 10-14-2025
- eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant Posted 09-15-2025
- The First Artificial Kidney Built in Canada has Ties to London: A Revolution in Care for Patients with Kidney Failure Posted 09-15-2025

